Form 4 CRISPR Therapeutics AG: Samarth Kulkarni (Director, CEO) For: 17 November
This article reports on a Form 4 filing for CRISPR Therapeutics AG, detailing transactions made by Samarth Kulkarni, the Director and CEO. The filing pertains to activity on November 17. The article provides the title of the filing and specifies the company and individual involved.
Precision BioSciences Inducement Awards to New Staff
Precision BioSciences, Inc. announced the grant of inducement awards to five new employees. These awards consist of an aggregate of 39,146 restricted stock units (RSUs) and were approved on November 16, 2026, under the company's 2021 Employment Inducement Incentive Award Plan and Nasdaq Listing Rule 5635(c)(4). The RSUs vest in substantially equal annual installments over three years, contingent on continued service.
What's Next for CVRx, Inc. Shareholders After 59.76% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Glancy Prongay Wolke & Rotter LLP has announced a class action lawsuit against CVRx, Inc. following a 59.76% stock drop, alleging the company misled investors between July 25, 2023, and August 6, 2026. The lawsuit stems from CVRx's disclosure of a civil investigative demand from the U.S. Department of Justice concerning potential false claims and kickbacks related to its Barostim device. Investors who suffered losses and wish to serve as lead plaintiff must file a motion by January 8, 2027.
AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
AbbVie (NYSE: ABBV) is scheduled to participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026. Management will host a fireside chat at 7:30 a.m. Central time, with a live audio webcast available on AbbVie's Investor Relations website. An archived version of the session will be accessible later the same day.
Worker asked for one mental health day - Caterpillar fired him, suit alleges
A Caterpillar worker has filed a federal lawsuit alleging disability discrimination, harassment, failure to accommodate, and retaliation after being fired the same day he requested a mental health day. The worker, who is legally blind in one eye and suffers from depression and anxiety, claims Caterpillar failed to engage in the "interactive process" required by the ADA to find a reasonable accommodation. The lawsuit highlights how common accommodation requests can escalate into federal litigation without proper HR protocols.
Form 4 CorMedix Inc. For: Nov 18 Filed by: Lefkowitz Steven W
This SEC Form 4 filing reports a change in beneficial ownership for Steven W. Lefkowitz, a Director of CorMedix Inc. (CRMD). On November 18, 2026, Lefkowitz acquired 11,500 shares of common stock at a price of $4.53 per share, increasing his direct beneficial ownership to 137,451 shares. The filing also notes indirect ownership through a money purchase plan and his wife.
At $4.53 a share, Steven W. Lefkowitz bought 11,500 CorMedix (CRMD) shares on Nov. 18.
CorMedix Inc. director Steven W. Lefkowitz purchased 11,500 common shares of CRMD at $4.53 per share on November 18, 2026. Following this transaction, he directly holds 137,451 shares and beneficially owns an additional 30,152 shares through a money purchase plan, plus 2,000 shares held by his wife. This insider activity, reported via an SEC Form 4 filing, signals a positive sentiment towards the company.
Why Is Walmart Stock Trading Higher Today? - Walmart (NASDAQ:WMT)
Walmart shares are trading higher today after the company reported better-than-expected third-quarter results and raised its guidance. Several analysts subsequently increased their price targets for WMT, maintaining bullish ratings. Despite headwinds from pharmacy deflation, analysts believe Walmart's underlying U.S. business remains healthy.
What Regeneron Pharmaceuticals Doubters Got Wrong
Regeneron Pharmaceuticals has seen a 25.9% increase in investor returns over the past year, outperforming bearish analyst predictions. Despite some setbacks like a failed melanoma trial, the company's FDA approvals for Livsayis and strong Q3 2026 revenues for Dupixent and EYLEA HD have largely validated the bullish outlook. The current stock price of US$923 reflects an assumption that product and partnership wins will continue to outweigh pricing and pipeline challenges.
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
Aprea Therapeutics (Nasdaq: APRE) announced positive interim results from its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in advanced solid tumors. The study showed promising clinical activity, including partial responses in uterine cancers and stable disease, with a favorable safety profile and effective WEE1 target engagement. Aprea plans to expand enrollment into focused cohorts, particularly in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer, to further evaluate the drug's efficacy in specific patient populations.
Robbins LLP Urges CVRX Shareholders Who Lost Money Investing in CVRx, Inc. to Contact the Firm for About Leading the Class Action
Robbins LLP is urging shareholders of CVRx, Inc. (NASDQAQ: CVRX) who incurred losses to contact the firm regarding a class action lawsuit. The lawsuit alleges that CVRx misled investors about illegal sales practices, including kickbacks and false claims to government health insurance programs, which artificially inflated revenue. These undisclosed activities increased the company's risk of criminal and civil liability, leading to a significant stock drop after the U.S. Department of Justice initiated an investigation.
What Drives Our Scientists: Dafydd Owen
Dafydd Owen, Senior Director, Medicinal Chemistry at Pfizer, finds deep purpose in his work, driven by the privilege of inventing molecules that can become life-saving medicines. Early in his career, he was inspired by a chemist whose invention benefited his own grandmother, solidifying his desire to contribute to medicine development for others. Owen emphasizes the creativity and profound responsibility involved in being a chemist who physically creates new molecules.
Kimberly-Clark completes Kenvue acquisition
Kimberly-Clark Corp. has completed its acquisition of Kenvue for US $48.8 billion, forming a consumer health and personal care giant. This merger brings together a $10 billion portfolio of brands including Huggies, Listerine, Kleenex, and Tylenol, enhancing the combined company's exposure to growing health and wellness categories. The deal is expected to generate approximately $1.9 billion in cost synergies and $500 million in incremental profit from revenue synergies.
Bruker a new Sector Perform at RBC as gains 'appear in the rearview'
RBC Capital Markets initiated coverage on Bruker (BRKR) with a Sector Perform rating, suggesting that the life sciences scientific instruments maker's opportunities for significant gains are now limited. Analyst Dan Leonard cited Bruker's innovation but balanced it against an over-reliance on semiconductor capital equipment for future outperformance and exposure to markets mismatched with current growth trends. Bruker shares were down approximately 7% following the announcement.
Ashland FY 2026: Revenue $1.86B, EPS $0.09 — 10-K Summary
Ashland (ASH) reported a significant improvement in its fiscal year 2026 financial performance, with sales increasing by 2% to $1.86 billion and net income returning to positive territory at $4 million, compared to a net loss of $845 million in the prior year. This turnaround was driven by higher volume and favorable foreign currency exchange rates, despite some offsets from unfavorable price/mix and the Avoca sale. The company also provided a fiscal 2027 outlook, projecting sales of $1.905 billion to $1.975 billion and adjusted EBITDA of $405 million to $435 million.
12 Health Care Stocks Moving In Friday's Intraday Session
This article identifies 12 healthcare stocks experiencing significant price movements during Friday's intraday trading session. It highlights top gainers like DataMEDS AI (MEDS), Akanda (AKAN), and Evolent Health (EVH), along with prominent losers such as Tessera Defense and Homeland Security (HLSQ) and Aprea Therapeutics (APRE), providing their respective percentage changes and market capitalization.
Danaher, Microsoft Build Open AI Agent Platform for Lab Instruments
Danaher Corporation has partnered with Microsoft Corp. to develop smart scientific instruments and an open, interoperable agentic platform for laboratory work, leveraging Microsoft Azure and Foundry for AI agents. The collaboration aims to accelerate research by assisting scientists in experimental planning, instrument control, real-time data interpretation, and follow-up recommendations. Preliminary internal tests showed significant efficiency gains for novice scientists using AI assistants.
J&J to install first Ottava robot in US hospital
Johnson & Johnson is set to install its first Ottava robotic surgery system at Memorial Hermann-Texas Medical Center, marking a significant step in the company's push into surgical robotics. This move follows the Ottava's FDA de novo authorization in July for 10 general surgery procedures and comes shortly after rival Medtronic expanded FDA clearance for its Hugo robot. The Ottava system is designed to improve workflow and efficiency, addressing challenges like operating room space constraints and increasing demand for robotic surgery.
3 Healthcare REITs Raised Their 2026 Outlooks as Senior Housing Demand Grows
Three healthcare REITs—Ventas, Welltower, and Healthpeak Properties—have raised their 2026 FFO guidance, benefiting from strong demographic demand as baby boomers age and historically low new senior housing supply. These REITs offer varying dividend yields and growth potentials, appealing to different income goals for retirees, with dividend safety relying on their respective FFO coverage and balance sheet health. Each company faces unique risks, including high valuations, refinancing challenges, and dilution from new share issuances.
Danaher Unveils Microsoft AI Partnership to Accelerate Scientific Experiments
Danaher Corporation has announced a strategic partnership with Microsoft Corp. to develop smart scientific instruments and an interoperable agentic ecosystem. This collaboration aims to streamline lab execution and make analytical insights more accessible by pairing Danaher's scientific expertise with Microsoft's AI capabilities, ultimately accelerating the translation of scientific findings into human impact. Initial commercial applications, including an AI assistant for high-content cellular imaging systems, are expected this year, with more agent-enabled instruments to follow in 2027.
HCA raises $6.5B in multi-part notes offering
HCA Inc., a subsidiary of HCA Healthcare, has successfully raised $6.5 billion through a public offering of senior notes, with proceeds allocated for general corporate purposes including debt redemption and repayment of borrowings. This significant capital raise, one of the largest post-IPO debt rounds in US healthcare, refinances existing debt and secures fixed-rate funding across maturities spanning from 2028 to 2056, demonstrating strong investor confidence in investment-grade healthcare paper. This data comes from Dealroom.co.
Buckle Posts Strong Q3 Results, Joins Evolent Health, Bending Spoons And Other Big Stocks Moving Higher On Friday
Buckle Inc. shares rose sharply after the company reported better-than-expected third-quarter financial results, beating analyst estimates for both earnings per share and sales. Other companies like Evolent Health, Gap Inc., and Bending Spoons also saw significant gains following positive financial news or analyst upgrades. The broader U.S. stock market was mixed, with the Nasdaq Composite experiencing a decline.
AstraZeneca leads European big pharma on growth, pipeline depth
AstraZeneca is identified by Citi as the leading European big pharma candidate due to its strong 22.8% Fair Value Upside, 7.3% LTM revenue growth, and the most extensive late-stage pipeline in the sector. Despite its high 23.9x P/E valuation, its R&D pipeline is considered "by far the best," with over $30 billion in unadjusted peak-sales potential from late-stage trials. While Sanofi SA offers better value and income with a 47.3% Fair Value Upside, its long-term outlook is weakened by pipeline setbacks.
Why Is Merck Stock Trading Higher Today? - Merck & Co (NYSE:MRK)
Merck & Co. announced that its Phase 3 TroFuse-015 trial for sacituzumab tirumotecan (sac-TMT) met its primary endpoint of overall survival in patients with advanced gastric cancer. This marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for this patient group. Despite not meeting the progression-free survival endpoint, the therapy demonstrated a consistent safety profile, leading to a positive market reaction for Merck's stock.
BMO Capital maintains Alnylam Pharmaceuticals at Outperform, raises price target to $293 from $292
BMO Capital has reiterated its Outperform rating for Alnylam Pharmaceuticals (ALNY) and slightly increased its price target from $292 to $293, suggesting a 98.2% upside from its November 19th closing price. This comes amid other recent analyst actions, with price targets ranging from $205 to $380 over the past 30 days.
Abivax Slides as New Short Thesis Adds Pressure Ahead of Obefazimod NDA Timeline
Abivax (ABVX) shares fell 15.9% today following a new short report challenging the strength of data for its lead drug, obefazimod, and raising concerns about regulatory risks. The report was published ahead of the planned U.S. NDA submission for obefazimod for ulcerative colitis by the end of 2026. Despite the stock decline, the company's September business update indicated a strong cash balance and runway into late 2029, suggesting the drop was not liquidity-driven.
Tyra Biosciences initiates Phase 2 SURF302 trial for oral FGFR3-selective inhibitor in NMIBC
Tyra Biosciences has commenced its Phase 2 SURF302 trial to evaluate an oral FGFR3-selective inhibitor for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). This initiative aims to provide new treatment options for patients who frequently experience disease recurrence. The company has previously published research on these inhibitors for urologic cancers, underscoring its commitment to targeted cancer therapies.
The Zacks Analyst Blog Highlights Cisco, UnitedHealth and Salesforce
Despite recent volatility in the Dow, Zacks Investment Research recommends three blue-chip stocks—Cisco Systems Inc. (CSCO), UnitedHealth Group Inc. (UNH), and Salesforce Inc. (CRM)—as strong "Buy" candidates. These companies are highlighted for their favorable Zacks Rank, robust guidance, solid estimate revisions, and significant price upside potential, making them attractive investments in a challenging market. The analysis provides detailed prospects and financial outlooks for each company.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Ecolab (ECL) is poised for continued growth due to its robust product portfolio, strong third-quarter 2026 performance, and focus on research and development, particularly in its Global High-Tech business. The company's acquisitions of Ovivo Electronics and CoolIT Systems are expanding its capabilities in ultrapure water purification and liquid cooling, while digital solutions and pest elimination platforms also contribute to its competitive advantage. However, cost fluctuations from raw materials, energy, and transportation remain a concern.
The Zacks Analyst Blog Highlights Cisco, UnitedHealth and Salesforce
This Zacks Analyst Blog highlights three blue-chip stocks—Cisco Systems Inc. (CSCO), UnitedHealth Group Inc. (UNH), and Salesforce Inc. (CRM)—that analysts recommend as "Buy" despite recent market volatility. Each company is discussed for its strong guidance, solid estimate revisions, and robust price upside potential, based on their respective business prospects and financial projections.
Lawsuit Claims Abbott Sales Reps Practiced Medicine Without a License While Adjusting Spinal Cord Stimulator
A South Carolina woman has filed a product liability lawsuit against Abbott Laboratories, alleging that unlicensed sales representatives practiced medicine without a license by repeatedly reprogramming her failed Proclaim spinal cord stimulator (SCS) rather than recommending its removal. The plaintiff, Tonia Holley, endured years of pain and electric shocks, only to discover later that the device's leads had migrated, making reprogramming futile. This lawsuit will join other similar Abbott SCS implant lawsuits in a multidistrict litigation (MDL).
Belite Bio Shares Drop 15% as FDA Delays Stargardt Drug Review to May 2027
Belite Bio's U.S.-listed shares fell over 15% after the FDA extended its review of tinlarebant, the company's lead therapy for Stargardt disease type 1, by three months, pushing the new PDUFA action date to May 12, 2027. Regulators requested more time to assess supplementary data, which delays a potential launch and related revenue, causing the stock to break a six-month support level. Despite the setback, Belite Bio remains confident in its clinical package, which includes positive Phase 3 DRAGON trial results.
Biodesix (BDSX) Shareholder Alert: Johnson Fistel Investigates Following Sales Force Challenges
Johnson Fistel, PLLP has launched an investigation into potential securities claims on behalf of Biodesix, Inc. (NASDAQ: BDSX) investors after the company's stock experienced a significant decline on November 6, 2026. This investigation follows Biodesix's announcement of reduced full-year 2026 revenue guidance and attributed disappointing growth partly to sales force challenges. The law firm is seeking to determine if Biodesix or its officers made materially false or misleading statements or failed to disclose crucial information to investors.
Elevance Health director Peru buys $383,860 in shares
Ramiro G. Peru, a director at Elevance Health Inc. (NYSE:ELV), recently acquired 1,000 shares of the company's common stock for a total of $383,860, with individual trades ranging from $383.62 to $383.92 per share. This purchase follows a 9.2% stock decline over the past week, though shares currently trade modestly higher than his purchase price. Elevance Health has also seen strong third-quarter 2026 earnings, surpassing estimates and leading multiple firms to raise their price targets.
MSMS Foundation and Molina Healthcare of Michigan Announce Provider Shortage Area Scholarship Recipients
The MSMS Foundation and Molina Healthcare of Michigan have announced the recipients of their Provider Shortage Area Scholarships, an initiative designed to address critical healthcare workforce shortages in Michigan's underserved communities. Five Michigan students—Whitney Bowyer, Selena Croskey, Jeren Ghoujeghi, Aden Smith, and Tiffany Tessmer—were selected for their academic excellence, financial need, and commitment to community-based care. These recipients plan to serve various medical fields in Detroit and rural northern Michigan, focusing on areas with significant healthcare access gaps.
Mizuho reiterates Outperform on Wave Life Sciences stock at $23 By Investing.com
Mizuho has reiterated an Outperform rating for Wave Life Sciences Ltd. (NASDAQ:WVE) with a $23 price target, citing positive regulatory alignment for the company’s alpha-1 antitrypsin deficiency program and the INHBE program as a potential value driver. The stock, currently trading at $2.71, is considered undervalued by InvestingPro analysis. Mizuho anticipates key catalysts in Q4 2026 and throughout 2027, including multidose data for WVE-006 and a clinical trial application for WVE-008.
Form 424B5 Cytosorbents Corp For: 20 November By Investing.com
This article announces the filing of Form 424B5 by Cytosorbents Corp on November 20. It references the stock symbol CTSO, which experienced a 14.62% decline. The brief piece primarily serves as a notification of the SEC filing.
Savara Inc stock hits 52-week low at $4.05 By Investing.com
Savara Inc. stock recently hit a 52-week low of $4.13, trading at $4.24, despite a strong 12.28% return over the past week. Analysts do not foresee profitability this year, and the stock may be overvalued relative to its Fair Value according to InvestingPro. However, there's optimism surrounding its drug Molbreevi, with H.C. Wainwright and Citizens reiterating "buy" and "Market Outperform" ratings respectively, both with a $10.00 price target, ahead of its PDUFA target action date of November 22, 2026.
Hopeful Week For Insiders Who Bought US$1.04m Of Tiziana Life Sciences Stock
Insiders at Tiziana Life Sciences Ltd recently saw an 11% stock price gain, recouping some losses from their US$1.04 million in share purchases over the past year. Despite the gain, insiders are still down US$338k on their investments, with the largest purchase made by CEO Ivor Elrifi at a price higher than the current market value. Insider ownership remains significant at 50%, suggesting alignment with shareholders and optimism for the company's future.
Why Is Bausch + Lomb Stock Falling Today? - Bausch & Lomb (NYSE:BLCO)
Bausch + Lomb Corporation's stock is falling after its topical eye drop BL1332 missed its primary pain-reduction endpoint in a Phase 2 study for post-PRK surgery pain. Although it failed the primary endpoint, the drug showed consistent directional pain relief, favorable safety, and suggested faster corneal healing. The company plans to review these findings with the FDA to guide future trial designs.
RBC raises Centene stock price target to $73 on earnings recovery
RBC Capital has increased its price target for Centene Corp. (NYSE:CNC) to $73 from $71, maintaining a Sector Perform rating, following strong third-quarter results and an impressive 88% return over the past year. The managed care company's earnings recovery is ahead of schedule, with Medicare Advantage reaching breakeven early and its prescription drug plan business delivering solid margins. InvestingPro analysis suggests Centene is currently undervalued, highlighting its "GREAT" financial health and offering additional investment insights.
Mizuho raises Incyte stock price target to $148 on execution By Investing.com
Mizuho has increased its price target for Incyte Corp. (NASDAQ: INCY) shares to $148 from $137, maintaining an Outperform rating due to strong execution and pipeline progress. This new target suggests a 27% upside and aligns with InvestingPro's undervalued assessment. The firm anticipates several catalysts, including data updates at the ASH conference and potential approval of 'povo' for hidradenitis suppurativa, to drive stock movement.
Jim Cramer Says Cardinal Health Is "the Stock That Is Made for This Moment"
Jim Cramer highlighted Cardinal Health (CAH) as "the stock that is made for this moment," noting its strong performance with shares climbing 34% year-to-date. The company recently beat earnings and revenue estimates, raised guidance, and renewed a critical contract with CVS through 2032. While the stock's valuation at 22x forward earnings suggests much of the rally is priced in, its defensive nature and consistent profitability make it a durable compounder for long-term investors.
Abbott starts trial of Encantor transcatheter aortic valve
Abbott has initiated the VOYAGER CE clinical trial for its investigational Encantor transcatheter aortic valve implantation system in Europe and Australia, targeting up to 300 severe aortic stenosis patients. This balloon-expandable system differentiates from Abbott's existing self-expanding Navitor TAVI system and aims to provide physicians with greater control and procedural confidence. The company plans a pivotal U.S. trial soon and will share early feasibility study data at PCR London Valves 2026.
4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover
This article highlights four dividend stocks—Pfizer, Bristol-Myers Squibb, T. Rowe Price, and United Parcel Service—that Wall Street has largely dismissed despite their strong balance sheets and ability to maintain dividend payouts. The author argues that despite market pessimism and analyst downgrades, these companies are well-positioned for recovery due to manageable debt, steady cash flow, and growing core businesses. Each company's financial health, dividend coverage, and unique strengths are detailed, emphasizing why the market's negative outlook may be overdone.
Jefferies reiterates Buy on Biomea Fusion stock, $5 target By Investing.com
Jefferies reiterated a Buy rating on Biomea Fusion Inc. (NASDAQ:BMEA) with a $5.00 price target, citing Icovamenib in Type 2 diabetes as a key near-term catalyst. The clinical-stage biotech is conducting Phase 2 trials for Icovamenib, with top-line data expected in Q1 and Q2 2027, and holds a strong liquidity position with cash extending into Q2 2027. This follows other positive analyst initiations and ratings, despite a recent cancellation of a public offering.
Jefferies Reiterates Buy Rating on Biomea Fusion Inc. (BMEA)
Jefferies analyst Roger Song has reiterated a Buy rating and a $5.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA). The analyst highlights Icovamenib in Type 2 Diabetes (T2D) as the primary near-term catalyst, with Phase 2 trial data expected in Q1 2027 and Q2 2027. Despite a financing overhang due to the company's cash runway extending only into Q2 2027, Icovamenib is seen as a potentially disease-modifying treatment for T2D, with additional programs in obesity and Type 1 Diabetes.
Form 4 Volitionrx Ltd: Cameron John Reynolds (Director, President and CEO) For: 20 November
This article reports on a Form 4 filing for Volitionrx Ltd, detailing insider transactions by Cameron John Reynolds, who serves as Director, President, and CEO. The filing is specific to November 20. The article is brief, focusing solely on the announcement of this regulatory filing.
Form 4 Volitionrx Ltd: Cameron John Reynolds (Director, President and CEO) For: 20 November By Investing.com
This article reports on a Form 4 filing for VolitionRx Ltd, specifically detailing a transaction involving Cameron John Reynolds, who serves as Director, President, and CEO. The filing is dated November 20th. The content is brief and primarily announces the existence of the SEC filing.
Belite Bio shares slide as FDA extends tinlarebant review by three months
Belite Bio Inc. shares dropped significantly after the FDA extended its review of tinlarebant, the company's lead retinal disease candidate, by three months. This delay pushes back the potential commercial launch of the drug, which aims to treat Stargardt disease type 1. Despite the setback, Belite Bio remains confident in its clinical data and will work with the agency.